Clinical Trial Update: Evaluating the Safety, Tolerability, and Effect of a Human Monoclonal Antibody (VRC01) on Markers of HIV Persistence in HIV-Infected Adults Receiving Antiretroviral Therapy (ART) [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating safety and tolerability of the monoclonal antibody VRC01 in HIV-infected adults on ART; completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• VRC01 (VRC01)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 1 | Status: COMPLETED | Results posted: 2017-07-31